Determine the necessary mass, volume, or concentration for preparing a solution.
| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
Moligand™, ≥98%(HPLC) Moligand™ for sensitive chromatographic and analytical workflows requiring minimal baseline interference.
Store at -20°C Ships Ice chest + Ice pads Check lot-specific COA for exact specifications.
SDS, COA, datasheet, and spec sheet available for download. Lot-specific COA accessible via lot number lookup.
Cited in 25 peer-reviewed publications across chromatography, organic synthesis, and cross-coupling reactions.
Valsartan is an angiotensin II receptor antagonist with IC50 of ranging from 39.5 to 116 μM. Valsartan is an orally active specific angiotensin II receptor blocker used for the treatment of hypertension
A nonpeptide angiotensin II AT1 receptor antagonist.
| ALogP | 4.4 |
|---|
| Sonrisas canónicas | CCCCC(=O)N(CC1=CC=C(C=C1)C2=CC=CC=C2C3=NNN=N3)C(C(C)C)C(=O)O |
|---|---|
| IUPAC Name | (2S)-3-methyl-2-[pentanoyl-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]amino]butanoic acid |
| InChIKey | ACWBQPMHZXGDFX-QFIPXVFZSA-N |
| INCHI | 1S/C24H29N5O3/c1-4-5-10-21(30)29(22(16(2)3)24(31)32)15-17-11-13-18(14-12-17)19-8-6-7-9-20(19)23-25-27-28-26-23/h6-9,11-14,16,22H,4-5,10,15H2,1-3H3,(H,31,32)(H,25,26,27,28)/t22-/m0/s1 |
| Isómeros SMILES | CCCCC(=O)N(CC1=CC=C(C=C1)C2=CC=CC=C2C3=NNN=N3)[C@@H](C(C)C)C(=O)O |
| WGK Alemania | 3 |
| CAS alternativo | 137862-53-4 |
| Número NSC | 758927 |
| Términos de entrada MeSH | 48933, CGP;CGP 48933;Diovan;Kalpress;Miten;N-valeryl-N-((2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl)valine;Nisis;Provas;Tareg;Vals;valsartan |
| Peso molecular | 435.52 |
| Reaxy-Rn | 24721853 |
| Reaxys-RN_link_address | https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN=24721853&ln= |
Comprehensive hazard, handling, storage, and regulatory compliance document.
Download SDS →Lot-specific quality data. Enter your lot number to retrieve the exact COA.
Look up COA →Full quality attributes and acceptance criteria for this grade.
View spec sheet →Taxonomy Tree
| Kingdom | Organic compounds |
|---|---|
| Superclass | Organic acids and derivatives |
| Clase | Carboxylic acids and derivatives |
| Subclass | Amino acids, peptides, and analogues |
| Intermediate Tree Nodes | Amino acids and derivatives - Alpha amino acids and derivatives |
| Direct Parent | Valine and derivatives |
| Alternative Parents | N-acyl-L-alpha-amino acids Biphenyls and derivatives Phenyltetrazoles and derivatives N-acyl amines Tertiary carboxylic acid amides Heteroaromatic compounds Monocarboxylic acids and derivatives Carboxylic acids Azacyclic compounds Organopnictogen compounds Organonitrogen compounds Organic oxides Hydrocarbon derivatives Carbonyl compounds |
| Molecular Framework | Aromatic heteromonocyclic compounds |
| Substituents | N-acyl-alpha-amino acid - Valine or derivatives - N-acyl-alpha amino acid or derivatives - N-acyl-l-alpha-amino acid - Biphenyl - Phenyltetrazole - Monocyclic benzene moiety - N-acyl-amine - Benzenoid - Azole - Heteroaromatic compound - Tertiary carboxylic acid amide - Tetrazole - Carboxamide group - Monocarboxylic acid or derivatives - Carboxylic acid - Azacycle - Organoheterocyclic compound - Organooxygen compound - Organonitrogen compound - Hydrocarbon derivative - Organic oxide - Organopnictogen compound - Carbonyl group - Organic nitrogen compound - Organic oxygen compound - Aromatic heteromonocyclic compound |
| Descripción | This compound belongs to the class of organic compounds known as valine and derivatives. These are compounds containing valine or a derivative thereof resulting from reaction of valine at the amino group or the carboxy group, or from the replacement of any hydrogen of glycine by a heteroatom. |
| External Descriptors | monocarboxylic acid - monocarboxylic acid amide - biphenylyltetrazole |
| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
Find and download the COA for your product by matching the lot number on the packaging.
| Lot Number | Certificate Type | Fecha | Articulo |
|---|---|---|---|
| Certificate of Analysis | May 07, 2026 | V129241 | |
| Certificate of Analysis | Dec 27, 2025 | V129241 | |
| Certificate of Analysis | Dec 27, 2025 | V129241 | |
| Certificate of Analysis | Dec 27, 2025 | V129241 | |
| Certificate of Analysis | Jul 18, 2025 | V129241 | |
| Certificate of Analysis | Dec 11, 2024 | V129241 | |
| Certificate of Analysis | Dec 11, 2024 | V129241 | |
| Certificate of Analysis | Sep 20, 2023 | V129241 | |
| Certificate of Analysis | Sep 20, 2023 | V129241 | |
| Certificate of Analysis | Jan 16, 2023 | V129241 | |
| Certificate of Analysis | Jan 05, 2023 | V129241 | |
| Certificate of Analysis | Jan 05, 2023 | V129241 | |
| Certificate of Analysis | Jan 05, 2023 | V129241 | |
| Certificate of Analysis | Jun 10, 2022 | V129241 | |
| Certificate of Analysis | Apr 25, 2022 | V129241 |
| Solubilidad | Soluble in Ethanol and Methanol |
|---|---|
| Sensibilidad | Moisture sensitive |
| Rotación específica [α] | -65°C |
| Punto de fusión (°C) | 117°C |
| Peso molecular | 435.500 g/mol |
| XLogP3 | 4.400 |
| Hydrogen Bond Donor Count | 2 |
| Hydrogen Bond Acceptor Count | 6 |
| Rotatable Bond Count | 10 |
| Exact Mass | 435.227 Da |
| Monoisotopic Mass | 435.227 Da |
| Topological Polar Surface Area | 112.000 Ų |
| Heavy Atom Count | 32 |
| Formal Charge | 0 |
| Complexity | 608.000 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 1 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| The total count of all stereochemical bonds | 0 |
| Covalently-Bonded Unit Count | 1 |
| 1. Qinglin Wang, Hao Yuan, Xinyue Pan, Yiling Yang, Xiaosong Ma, Yahui Guo. (2023) Synthesis of silver nanoclusters using a double-stranded DNA template and its application for captopril detection. JOURNAL OF FOOD COMPOSITION AND ANALYSIS, [PMID:] [10.1016/j.jfca.2023.105825] |
| 2. Huimin Zhou, Zhiwei Qiu, Jin Zeng, Ruobin Dai, Zhiwei Wang. (2023) Ultra-permeable polyamide nanofiltration membrane modified by hydrophilic-hydrophobic alternated lignocellulosic nanofibrils for efficient water reuse. JOURNAL OF MEMBRANE SCIENCE, [PMID:] [10.1016/j.memsci.2023.122125] |
| 3. Zhiren Zou, Qiang Huang, Xiaobo Li, Xianzhi Liu, Lina Yin, Yunjie Zhao, Guang Liang, Wenqi Wu. (2023) Dissolution changes in drug-amino acid/biotin co-amorphous systems: Decreased/increased dissolution during storage without recrystallization. EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, [PMID:37442486] [10.1016/j.ejps.2023.106526] |
| 4. Mingkang Zhang, Ruirui Cui, Yan Zhou, Yanrong Ma, Yongwen Jin, Lina Wang, Wen Kou, Xin’an Wu. (2023) Accumulation of Renal Fibrosis in Hyperuricemia Rats Is Attributed to the Recruitment of Mast Cells, Activation of the TGF-β1/Smad2/3 Pathway, and Aggravation of Oxidative Stress. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 24 (13): (10839). [PMID:37446016] [10.3390/ijms241310839] |
| 5. Yupeng Shi, Mengyang Zhou, Shuo Zhao, Haotian Li, Wenhao Wang, Jingliang Cheng, Lin Jin, Yifei Wang. (2023) Janus amphiphilic nanofiber membranes synergistically drive antibacterial and anti-inflammatory strategies for skin wound healing. MATERIALS & DESIGN, [PMID:] [10.1016/j.matdes.2023.111778] |
| 6. Qiang Huang, Zhiren Zou, Xiaobo Li, Qinwen Xiao, Guang Liang, Wenqi Wu. (2023) Poly (amino acid)s as new co-formers in amorphous solid dispersion. INTERNATIONAL JOURNAL OF PHARMACEUTICS, [PMID:36706970] [10.1016/j.ijpharm.2023.122645] |
| 7. Mingkang Zhang, Ruirui Cui, Yan Zhou, Yanrong Ma, Yongwen Jin, Xueyan Gou, Jinru Yang, Xin’an Wu. (2022) Uric acid accumulation in the kidney triggers mast cell degranulation and aggravates renal oxidative stress. TOXICOLOGY, [PMID:36464070] [10.1016/j.tox.2022.153387] |
| 8. Lin Chen, Li Ge, Qinghui Liang, Zhenbo Zhao, Kedi Yang. (2022) Eutectic solvents formed by (+)-DTTA and L-menthol as novel chiral recognition and separation media for enantioselective extraction of valsartan enantiomers. JOURNAL OF MOLECULAR LIQUIDS, [PMID:] [10.1016/j.molliq.2022.120818] |
| 9. Ke Lin, Wu Luo, Na Yang, Lan Su, Hao Zhou, Xiang Hu, Yi Wang, Zia A. Khan, Weijian Huang, Gaojun Wu, Guang Liang. (2022) Inhibition of MyD88 attenuates angiotensin II-induced hypertensive kidney disease via regulating renal inflammation. INTERNATIONAL IMMUNOPHARMACOLOGY, [PMID:36116148] [10.1016/j.intimp.2022.109218] |
| 10. Wang Yiran, Shi Jihua, Dai Dapeng, Cai Jianping, Wang Shuanghu, Hong Yun, Zhou Shan, Zhao Fangling, Zhou Quan, Geng Peiwu, Zhou Yunfang, Xu Xue, Luo Qingfeng. (2022) Evaluation of commonly used cardiovascular drugs in inhibiting vonoprazan metabolism in vitro and in vivo. Frontiers in Pharmacology, [PMID:36052128] [10.3389/fphar.2022.909168] |
| 11. Yan Zhou, Mengmeng Wei, Mingkang Zhang, Jianping Zhang, Fabing Tang, Xin’an Wu. (2022) Adefovir accumulation in the renal interstitium triggers mast cell degranulation and promotes renal interstitial fibrosis. TOXICOLOGY LETTERS, [PMID:35114312] [10.1016/j.toxlet.2022.01.018] |
| 12. Xiao Juan Liu, Yang Zhang, Xue Zhong Wang. (2020) Study on Co-Crystallization of LCZ696 Using In Situ ATR-FTIR and Imaging. Crystals, 10 (10): (922). [PMID:] [10.3390/cryst10100922] |
| 13. Qi Liang, Xiaoying Fu, Jianfeng Zhang, Jiaxue Hao, Gangjun Feng, Jing Wang, Qian Li, Faizan Ahmad, Xinfeng Zhao. (2020) Immobilized angiotensin II type I receptor: A powerful method of high throughput screening for antihypertensive compound identification through binding interaction analysis. JOURNAL OF CHROMATOGRAPHY A, [PMID:32156458] [10.1016/j.chroma.2020.461003] |
| 14. Yi-Lin Sun, Peng-Hui Li, Ling Shi, Wan-Zhen Su, De-Sheng Li, Gen-Long Xue, Yue Zhao, Chang-Zhu Li, Ying Li, Yang Zhou, Shang-Xuan Li, Yang Zhang, Yan-Jie Lu, Zhen-Wei Pan. (2018) Valsartan reduced the vulnerability to atrial fibrillation by preventing action potential prolongation and conduction slowing in castrated male mice. JOURNAL OF CARDIOVASCULAR ELECTROPHYSIOLOGY, 29 (10): (1436-1443). [PMID:30016000] [10.1111/jce.13697] |
| 15. Xiaohua Xu, Yongzhi Xu, Shengqiang Liang. (2024) Analytical Interference in Chemiluminescence Assay–Measured Angiotensin I, Angiotensin II, Aldosterone, and Renin. JOURNAL OF CLINICAL LABORATORY ANALYSIS, 38 (10): (e25045). [PMID:38822626] [10.1002/jcla.25045] |
| 16. Jia-Huan He, Xiang-Jun Li, Shi-Peng Wang, Xia Guo, Hao-Xuan Chu, Han-Chi Xu, Yu-Shi Wang. (2024) Eugenol Inhibits Ox-LDL-Induced Proliferation and Migration of Human Vascular Smooth Muscle Cells by Inhibiting the Ang II/MFG-E8/MCP-1 Signaling Cascade. Journal of Inflammation Research, [PMID:38328560] [10.2147/JIR.S446960] |
| 17. Huixiang Zhang, Yang Zhang, Fumin Xue, Hui Chen, Zhenguo Gao, Shichao Du, Yan Wang. (2024) Insight into the dissolution behavior of valsartan (form E) in twelve pure solvents: Solubility, modelling and molecular simulation. JOURNAL OF MOLECULAR LIQUIDS, [PMID:] [10.1016/j.molliq.2024.124774] |
| 18. Wen Luo, Zhenzhen Li, Junjie Che, Xinyao Li, Huali Zhang, Jinxiu Tian, Chunyang Wang, GuiYing Li, Lin Jin. (2024) Near-Infrared Responsive Nanocomposite Hydrogel Dressing with Anti-Inflammation and Pro-Angiogenesis for Wound Healing. ACS Applied Materials & Interfaces, [PMID:38934381] [10.1021/acsami.4c06193] |
| 19. Chenglin Liang, Ge Zhang, Linlin Guo, Xinyi Ding, Heng Yang, Hongling Zhang, Zhenzhong Zhang, Lin Hou. (2024) Spatiotemporal transformable nano-assembly for on-demand drug delivery to enhance anti-tumor immunotherapy. Asian Journal of Pharmaceutical Sciences, [PMID:38434719] [10.1016/j.ajps.2024.100888] |
| 20. Detao Li, Wenqian Chen, Limin Zhou, Li Xu, Feiqiang He, Jerry Y Y Heng, Hamza Shehzad, Jinbo Ouyang. (2024) Uncovering Cocrystal Formation and Competition Mechanism of Polyhydroxy Natural Products: Cases of Quercetin, Hesperidin, Resveratrol, and Curcumin. CRYSTAL GROWTH & DESIGN, [PMID:] [10.1021/acs.cgd.4c00291] |
| 21. Ramsha Khalid, Syed Mahmood, Zarif Mohamed Sofian, Zamri Chik, Yi Ge. (2025) Development of Rapidly Dissolving Microneedles Integrated with Valsartan-Loaded Nanoliposomes for Transdermal Drug Delivery: In Vitro and Ex Vivo Evaluation. Pharmaceutics, 17 (4): (483). [PMID:40284478] [10.3390/pharmaceutics17040483] |
| 22. Fei Lingyan, Wang Honghong, Zhao Dongliang, Wang Xiaohua, Ren Jizhen, Liu Lanyun, Tang Chun, Lei Yan, Wang Qingqing, Nie Yuanpeng, Liu Yang, Li Na, Zhong Ming, Xu Nan, Wei Jin, Persson Pontus B., Patzak Andraes, Khedkar Pratik H., Zheng Zhihua, Jiang Shan. (2025) Rescuing vascular dysfunction in dorsal pancreatic arteries prevents tacrolimus-induced glucose metabolism disorder in mice. MOLECULAR MEDICINE, 31 (1): (1-15). [PMID:40495121] [10.1186/s10020-025-01282-7] |
| 23. Rongrong Xue, Tuanjia Li, Yingying He, Fenghua Chen, Wang-Chuan Xiao. (2026) Supercooled Liquid during the Evaporation and Cooling Crystallization of Valsartan:A Macroscopic Observation. CRYSTENGCOMM, [PMID:] [10.1039/D5CE01019E] |
| 24. Yunshan Wang, Nan Lu, Peiyao Wu, Yue Chu, Yonghao Xing, Jing Wang, Xinfeng Zhao. (2026) An Allosteric Assay for Identifying Ligands Binding to β2 Adrenergic Receptor by Surface-Enhanced Raman Scattering (SERS)-Active Nanoparticles. ANALYTICAL CHEMISTRY, [PMID:41637639] [10.1021/acs.analchem.5c07045] |
| 25. Lingyan Fei, Xiaohua Wang, Lingyi Kong, Tianjiao Cui, Pratik H Khedkar, Yunxiu Xiang, Dongliang Zhao, Junxuan Fang, Yulin Liang, Yangyang Zhang, Nan Xu, Xingyu Qiu, Liang Zhao, Gensheng Zhang, Yan Lei, Chun Tang, Kongyang Ma, Liwei Lu, Jin Wei, En Yin Lai, Pontus B Persson, Andreas Patzak, Zhihua Zheng, Shan Jiang. (2026) Tacrolimus Induced Hypertension and Vascular Remodeling Includes Mechanisms of Cellular Senescence—The Protective Effect of Valsartan. Acta Physiologica, 242 (4): (e70189). [PMID:41814130] [10.1111/apha.70189] |
Our grade selection guide covers purity, stabilizer status, and application suitability for all variants in our catalog.
View Moligand™ grade guide →